Is Buying Innovate Biopharmaceuticals, Inc. (INNT) Here a Winning Strategy?

March 18, 2018 - By Michael Pereira

The stock of Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) is a huge mover today! The stock increased 12.77% or $1.8 during the last trading session, reaching $15.9. About 175,701 shares traded. Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 6 months positive chart setup for the $14.98 million company. It was reported on Mar, 18 by We have $16.38 PT which if reached, will make NASDAQ:INNT worth $449,340 more.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. The company has market cap of $14.98 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH). It currently has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: